A series of compounds bearing heterocyclic substituents were prepared,
and evaluated for inhibition of the ACAT enzyme. The heterocyclic gro
ups were compared in terms of in vitro potency against their diarylimi
dazole analogues. Data for the purposes of QSAR were also collected. O
ur goal is a systemic ACAT inhibitor, which would be a potential antih
ypercholesterolemic and antiatherosclerotic agent.